This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Biotech Stock Roundup: AMGN & INCY Focus on Coronavirus Treatments, & More
by Zacks Equity Research
The biotech sector is in focus with pipeline updates from companies evaluating treatments for the novel COVID-19.
Immunomedics Up as Breast Cancer Drug Study Shows Efficacy
by Zacks Equity Research
Immunomedics (IMMU) soars as the phase III study on breast cancer drug shows efficacy and will be subsequently halted.
Immunomedics (IMMU) in Focus: Stock Moves 5% Higher
by Zacks Equity Research
Immunomedics (IMMU) saw a big move last session, as its shares jumped nearly 5% on the day, amid huge volumes.
Why Is Immunomedics (IMMU) Down 18% Since Last Earnings Report?
by Zacks Equity Research
Immunomedics (IMMU) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Options Traders Expect Huge Moves in Immunomedics (IMMU) Stock
by Zacks Equity Research
Investors need to pay close attention to Immunomedics (IMMU) stock based on the movements in the options market lately.
Immunomedics (IMMU) Reports Wider-Than-Expected Q4 Loss
by Zacks Equity Research
Immunomedics (IMMU) posts wider-than-expected Q4 loss. Its BLA seeking accelerated approval for sacituzumab govitecan in metastatic triple-negative breast cancer (mTNBC) is accepted for filing by FDA.
Exelixis (EXEL) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Investors are looking forward to Cabometyx's performance and pipeline updates, when Exelixis (EXEL) reports Q4 results.
What Awaits Jazz Pharmaceuticals (JAZZ) in Q4 Earnings?
by Zacks Equity Research
Progress of its pipeline candidates and launch of Sunosi is likely to have increased Jazz Pharmaceuticals (JAZZ) operating expenses in the fourth quarter. Xyrem likely to have continued strong demand trend.
Why Earnings Season Could Be Great for Immunomedics (IMMU)
by Zacks Equity Research
Immunomedics (IMMU) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
What's in Store for Jounce (JNCE) This Earnings Season?
by Zacks Equity Research
Investors will look forward to pipeline updates when clinical-stage immunotherapy company, Jounce (JNCE), reports Q4 results.
What Awaits Spectrum Pharmaceuticals (SPPI) in Q4 Earnings?
by Zacks Equity Research
Progress of its pipeline candidates is likely to have increased Spectrum Pharmaceuticals' (SPPI) operating expenses in the fourth quarter.
What's in Store for Aimmune (AIMT) This Earnings Season?
by Zacks Equity Research
Aimmune (AIMT) is likely to provide an update on Palforzia's launch plans during Q4 investors' call. The drug gets an approval in January 2020 for the treatment of peanut allergy.
Is a Beat in the Cards for Clovis' (CLVS) Earnings in Q4?
by Zacks Equity Research
Clovis' (CLVS) sole marketed drug, Rubraca, is likely to have driven revenues in the fourth quarter.
What's in Store for Corcept (CORT) This Earnings Season?
by Zacks Equity Research
During Corcept's (CORT) Q4 earnings call, investor focus will be on the sales uptake of its Cushing's syndrome drug Korlym and other pipeline updates.
What Awaits Intra-Cellular Therapies (ITCI) in Q4 Earnings?
by Zacks Equity Research
Intra-Cellular Therapies (ITCI) is likely to provide update on its commercialization plan for Caplyta, approved for treating schizophrenia in December 2019, on the Q4 call.
Mylan (MYL) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Investors will look forward to regular top and bottom-line numbers and updates on merger with Upjohn, when Mylan (MYL) reports Q4 results.
5 Drug/Biotech Stocks Likely to Beat Q4 Earnings Estimates
by Zacks Equity Research
Let us take a look at some drug/biotech stocks that are poised to beat on earnings in the fourth quarter.
Incyte (INCY) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on regular top and bottom-line numbers along with pipeline updates, when Incyte (INCY) reports fourth-quarter 2019 results.
Immunomedics Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Immunomedics has been struggling lately, but the selling pressure may be coming to an end soon.
FDA Accepts Immunomedics' BLA Refiling for Breast Cancer Drug
by Zacks Equity Research
The FDA accepts Immunomedics' (IMMU) BLA resubmission for sacituzumab govitecan to treat patients with metastatic triple-negative breast cancer, having received at least two prior therapies.
Company News For Dec 27, 2019
by Zacks Equity Research
Companies In The News Are: QGEN, IMMU, CANF, SBPH
4 Drug/Biotech Outperformers That May Lose Steam in 2020
by Kinjel Shah
Here we discuss some biotech stocks, which are up this year so far but might not be good additions to your portfolio.
Are Options Traders Betting on a Big Move in Immunomedics (IMMU) Stock?
by Zacks Equity Research
Investors need to pay close attention to Immunomedics (IMMU) stock based on the movements in the options market lately.
Immunomedics Resubmits Application for Breast Cancer Drug
by Zacks Equity Research
Immunomedics (IMMU) resubmits BLA to the FDA for sacituzumab govitecan for the treatment of patients with metastatic triple-negative breast cancer, who have received at least two prior therapies.
Implied Volatility Surging for Immunomedics (IMMU) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Immunomedics (IMMU) stock based on the movements in the options market lately.